Literature DB >> 29372411

[S1 guideline - Austrian consensus for anticoagulation in the context of atrial fibrillation ablation].

Martin Martinek1, Marianne Gwechenberger2, Daniel Scherr3, Clemens Steinwender4, Markus Stühlinger5, Helmut Pürerfellner1, Franz Xaver Roithinger6, Lukas Fiedler6.   

Abstract

In summary, uninterrupted oral antikoagulation can be recommended, with different recommendation classes and levels of evidence, for both, VKA and NOAC therapy, in the framework of PVI. Even with low CHA2DS2 VASc scores, OAK is indicated 3-4 weeks before and 8 weeks after the procedure. Periinterventional bridging with heparins should be avoided due to increased bleeding events.The present Consensus provides recommendations on the current state of knowledge and has been prepared exclusively by members of the Rhythmology Working Group of the Austrian Cardiological Society who have great practical experience in catheter ablation and peri-interventional OAK in patients with atrial fibrillation. Publication of new randomized and controlled studies on the subject are expected in the coming months, so that there will certainly be changes in the recommendations. The Rhythmology Working Group of the Austrian Cardiological Society will strive to keep this S1 guideline regularly up to date. We hope that this consensus is used to increase the safety for patients undergoing PVI and to provide physicians with a homogeneous approach in Austria.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Consensus; Non-vitamin k oral anticoagulants (NOAC); Vitamin K antagonists (VKA)

Mesh:

Substances:

Year:  2018        PMID: 29372411     DOI: 10.1007/s00508-017-1310-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  53 in total

1.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

Review 2.  New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin.

Authors:  Yue Zhao; Yuan Yang; Xuejiao Tang; Xiang Yu; Lei Zhang; Hua Xiao
Journal:  J Interv Card Electrophysiol       Date:  2017-01-12       Impact factor: 1.900

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

Review 4.  Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Authors:  Aref A Bin Abdulhak; Abdur Rahman Khan; Imad M Tleyjeh; John A Spertus; Susan U Sanders; Kristy E Steigerwalt; Musa A Garbati; Reem A Bahmaid; Alan P Wimmer
Journal:  Europace       Date:  2013-08-16       Impact factor: 5.214

5.  Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging.

Authors:  Oussama M Wazni; Antonio Rossillo; Nassir F Marrouche; Eduardo B Saad; David O Martin; Mandeep Bhargava; Dianna Bash; Salwa Beheiry; Mark Wexman; Domenico Potenza; Ennio Pisano; Raffaele Fanelli; Aldo Bonso; Sakis Themistoclakis; Demet Erciyes; Walid I Saliba; Robert A Schweikert; Johannes Brachmann; Antonio Raviele; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2005-06

6.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

7.  Atrial fibrillation ablation in patients with therapeutic international normalized ratios.

Authors:  Martin Schmidt; Nathan M Segerson; Harald Marschang; Nazem Akoum; Harald Rittger; Sarah M Clifford; Johannes Brachmann; Marcos Daccarett; Nassir F Marrouche
Journal:  Pacing Clin Electrophysiol       Date:  2009-08       Impact factor: 1.976

8.  Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Mohamed Bassiouny; Walid Saliba; John Rickard; Mingyuan Shao; Albert Sey; Mariam Diab; David O Martin; Ayman Hussein; Maurice Khoury; Bernard Abi-Saleh; Samir Alam; Jay Sengupta; P Peter Borek; Bryan Baranowski; Mark Niebauer; Thomas Callahan; Niraj Varma; Mina Chung; Patrick J Tchou; Mohamed Kanj; Thomas Dresing; Bruce D Lindsay; Oussama Wazni
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-04-03

9.  Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.

Authors:  Taishi Kuwahara; Mitsunori Abe; Masaru Yamaki; Hiroyuki Fujieda; Yumiko Abe; Katsushi Hashimoto; Misako Ishiba; Hirotsuka Sakai; Keiichi Hishikari; Masateru Takigawa; Kenji Okubo; Katsumasa Takagi; Yasuaki Tanaka; Jun Nakajima; Atsushi Takahashi
Journal:  J Cardiovasc Electrophysiol       Date:  2016-02-12

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.